family with sequence similarity 237 member AGenealiases: []
Q-omics provides the consensus-scored FAM237A profile across patient tissues and cancer cell-line models. FAM237A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM237A is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, FAM237A RNA expression shows 11,780 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where FAM237A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM237A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM237A survival associations across molecular data types. FAM237A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM237A RNA expression–survival associations across cancer types. High FAM237A expression shows unfavorable associations in UVM, THYM, KIRC and COAD, but favorable associations in UCEC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM237A RNA expression.
This table summarizes FAM237A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM237A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM237A shows lower tumor expression in BRCA and THCA and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher FAM237A RNA expression in tumor versus normal tissue (log2 FC = +0.106, t-test p = .003).
This table shows molecular features associated with FAM237A in patient tissues and cancer cell lines. In patient samples, FAM237A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM237A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
